Attached files
| file | filename |
|---|---|
| 8-K - Inspyr Therapeutics, Inc. | v172906_8-k.htm |
CONTACT:
|
Company:
|
Craig
Dionne, Ph.D., CEO
|
GenSpera,
Inc. (210) 479-8112
|
Investors:
|
Steve
Chizzik
|
The
Verrazano Group (908) 688-9111
|
Media:
|
Deanne
Eagle
|
Planet
Communications (917) 837-5866
GENSPERA
RECEIVES PATENT ON SECOND ANTI-CANCER DRUG, G-115
SAN ANTONIO, Texas,
February 2, 2010 –
GenSpera, Inc. (OTC.BB: GNSZ) announced
that its patent application, entitled “Tumor Activated Prodrugs,” has been
issued by the United States Patent and Trademark Office (USPTO) as US Patent
7,635,682. The patent covers the composition and potential uses of
G-115, GenSpera’s second anti-cancer drug in development.
“The
issuance of this patent further strengthens our intellectual property position
for G-115 and its use in prostate cancer and other prostate pathologies
including enlarged prostate,” commented Dr. Craig Dionne, Ph.D.,
GenSpera CEO and President. “We are also pleased that the term of this patent
will extend into the year 2026, which is a very important feature when we enter
discussions with future development partners.”
G-115 is
a pro-drug that is selectively activated within prostate tumors by an enzyme,
Prostate Specific Antigen (PSA), which is active only within prostate tissue and
prostate cancer tumors. In preclinical testing, G-115 was shown to
dramatically inhibit the growth of tumors in animal models of human prostate
cancer. GenSpera, Inc. owns and controls all rights to G-115 and anticipates a
strategic partnership to maximize the value of the drug as it progresses through
future clinical trials.
About
GenSpera
GenSpera,
Inc. is a development stage oncology company focused on therapeutics that
deliver a potent, unique and patented drug directly to tumors. GenSpera’s
technology platform combines a potent cytotoxin (12ADT) with a pro-drug delivery
system that activates the drug only within the tumor. Unlike standard cancer
drugs, plant-derived 12ADT kills cells independent of their division rate, thus
making it effective at killing all fast- and slow-growing cancers and cancer
stem cells. GenSpera’s pro-drug platform is the subject of seven issued patents
with three additional patents pending.
GenSpera
initiated a Phase I cancer trial with its lead drug, G-202, early in the first
quarter of 2010. G-202 targets the established blood vessels that nourish solid
tumors, thus destroying the tumor’s blood supply. This is a dramatic improvement
upon anti-angiogenic drugs that primarily only stop the growth of new blood
vessels. Upon completion of its Phase I trial, GenSpera expects to initiate
multiple Phase II trials for G-202 in several different cancer types. The
company’s second drug, G-115, will directly target prostate cancer.
GenSpera,
Inc. owns and controls all rights to G-202 and G-115 and anticipates a strategic
partnership to maximize the value of the drugs as they progress through future
clinical trials.
For more
information, please visit the Company’s website: www.genspera.com.
Cautionary Statement Regarding
Forward Looking Information
This news
release may contain forward-looking statements made pursuant to the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Investors are cautioned that such forward-looking statements in this press
release regarding potential applications of GenSpera’s technologies constitute
forward-looking statements that involve risks and uncertainties, including,
without limitation, risks inherent in the development and commercialization of
potential products, uncertainty of clinical trial results or regulatory
approvals or clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking statements.
Additional information on potential factors that could affect our results and
other risks and uncertainties will be detailed from time to time in GenSpera’s
periodic reports.
# # #